The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict CME Group's revenues will compress -8.0% and EPS will wane -8.8%.
The average estimate for revenue is $712.3 million. On the bottom line, the average EPS estimate is $0.73.
Last quarter, CME Group booked revenue of $660.9 million. GAAP reported sales were 10% lower than the prior-year quarter's $736.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.63. GAAP EPS of $0.50 for Q4 were 78% lower than the prior-year quarter's $2.25 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 97.1%, 20 basis points worse than the prior-year quarter. Operating margin was 56.8%, 380 basis points better than the prior-year quarter. Net margin was 25.2%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $2.97 billion. The average EPS estimate is $3.14.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 757 members out of 807 rating the stock outperform, and 50 members rating it underperform. Among 199 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 187 give CME Group a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CME Group is outperform, with an average price target of $57.26.
Looking for alternatives to CME Group? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add CME Group to My Watchlist.